The effect of a new gastric proton pump inhibitor on serotonin-induced gastric mucosal lesions in rats

1988 ◽  
Vol 23 (5) ◽  
pp. 501-505
Author(s):  
Yoshihisa Tsukamoto ◽  
Saburo Nakazawa ◽  
Kose Segawa ◽  
Hidemi Goto ◽  
Akira Fukui ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Mucosal Lesions ◽  
Gastric Proton Pump ◽  
Mucosal Lesions

Suppression of Helicobacter pylori-induced Angiogenesis by a Gastric Proton Pump Inhibitor

2005 ◽  
Vol 5 (3) ◽  
pp. 191
Author(s):  
Sung Ho Jin ◽  
Hwa Young Lee ◽  
Dong Kyu Kim ◽  
Yong Kwan Cho ◽  
Ki Baik Hahm ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Proton Pump

scholarly journals Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Gut ◽  
1983 ◽  
Vol 24 (4) ◽  
pp. 270-276 ◽  
Author(s):  
T Lind ◽  
C Cederberg ◽  
G Ekenved ◽  
U Haglund ◽  
L Olbe
Keyword(s):  
Proton Pump Inhibitor ◽  
Acid Secretion ◽  
Proton Pump ◽  
Gastric Proton Pump

scholarly journals Omeprazole, a Gastric Proton Pump Inhibitor, Inhibits Melanogenesis by Blocking ATP7A Trafficking

2015 ◽  
Vol 135 (3) ◽  
pp. 834-841 ◽  
Author(s):  
Mary S. Matsui ◽  
Michael J. Petris ◽  
Yoko Niki ◽  
Nevena Karaman-Jurukovska ◽  
Neelam Muizzuddin ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Gastric Proton Pump

scholarly journals Effects of Rabeprazole, a Gastric Proton Pump Inhibitor, on Biliary and Hepatic Lysosomal Enzymes in Rats

1998 ◽  
Vol 76 (3) ◽  
pp. 279-288 ◽  
Author(s):  
Hideaki Fujisaki ◽  
Kiyoshi Oketani ◽  
Jun-ichi Nagakawa ◽  
Osamu Takenaka ◽  
Yoshiharu Yamanishi
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Lysosomal Enzymes ◽  
Gastric Proton Pump

scholarly journals Management of Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Disease by Acid Suppression

1999 ◽  
Vol 13 (2) ◽  
pp. 135-142 ◽  
Author(s):  
R Lad ◽  
D Armstrong
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Nsaid Therapy ◽  
Peptic Ulceration ◽  
Acid Suppression ◽  
Gastric Ulcers ◽  
Prostaglandin E ◽  
Duodenal Lesions ◽  
Mucosal Lesions ◽  
Anti Inflammatory

One major cause of peptic ulceration is the use of nonsteroidal anti-inflammatory drugs (NSAIDs). The precise mechanisms through which NSAIDs cause peptic ulceration are unknown, but the discovery that they reduce the production of ‘cytoprotective’ prostaglandins led to the hypothesis that coadministration of exogenous prostaglandins heals and prevents NSAID-induced gastroduodenal ulcers and other mucosal lesions. Studies using high doses of misoprostol have shown that it does have a protective effect; however, gastrointestinal intolerance of this prostaglandin E2analogue is common. Early indications that acid suppression was effective in the management of NSAID-related peptic ulcers came from studies showing that gastric ulcers could be healed by omeprazole in patients who continued to take NSAIDs. Other studies suggested that acid suppression reduces the incidence of mucosal lesions but that standard dose ranitidine protects only against duodenal lesions. Subsequent studies reported that higher dose H2receptor antagonist therapy can protect against both gastric and duodenal ulcers during continued NSAID therapy. An ideal therapeutic strategy would heal NSAID-related ulcers and prevent the development of new NSAID-related lesions and complications in patients who are unable to discontinue NSAID therapy. A number of recent studies indicate that effective acid-suppressive treatment with the proton pump inhibitor omeprazole can achieve these aims. Overall, data from recent studies show that acid suppression with the proton pump inhibitor omeprazole at a dose of 20 mg daily is the most effective means of healing NSAID-associated gastroduodenal lesions and that it is the most effective prophylactic therapy. In the long run, the role of omeprazole will have to be evaluated with respect to its cost effectiveness compared with other strategies and with respect to the development of less damaging NSAIDs.

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor

1996 ◽  
Vol 6 (1) ◽  
pp. 81-91 ◽  
Author(s):  
Mark VandenBranden ◽  
Barbara J. Ring ◽  
Shelly N. Binkley ◽  
Steven A. Wrighton
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Human Liver ◽  
Cytochromes P450 ◽  
Gastric Proton Pump
Sign in / Sign up

Export Citation Format

Share Document